Anti-GPC3 CAR T for Treating Patients With Advanced HCC

Phase 1

Completed

• Conditions: Hepatocellular Carcinoma
• Interventions: Biological: anti-GPC3 CAR T

• Registration Number: NCT02395250
• Lead Sponsor: RenJi Hospital

Brief Summary

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).

Detailed Description

Not available

Study Timeline

• Study Start: 2015-03
• Study First Submitted: 2015-03-17
• Study First Submitted QC: 2015-03-17
• Study First Posted: 2015-03-23
• Primary Completion: 2016-06
• Status Verified: 2018-11
• Study Completion: 2018-11
• Last Update Submitted: 2019-08-22
• Last Update Posted: 2019-08-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
anti-GPC3 CAR T	anti-GPC3 CAR T	-

Primary Outcome Measures

Name	Time	Method
Adverse events attributed to the administration of the anti-GPC3 CAR T cells	2 years

Trial Locations

Locations (1)

Shanghai Cancer Institute; 🇨🇳 Xuhui, Shanghai, China